

DemonstTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

NCT07358078

Status RECRUITING
Sponsor Alnylam Pharmaceuticals
Enrollment 2,000 participants

Key Eligibility Criteria

Inclusion (2)

- Has a diagnosis of ATTR-CM
- Is initiating treatment with vutrisiran or another approved ATTR-CM therapy

Exclusion (1)

- Is enrolled in an interventional clinical trial

Locations (3 total)

Clinical Trial Site, Naples, Florida, United States
Clinical Trial Site, New Brunswick, New Jersey, United States
Clinical Trial Site, Memphis, Tennessee, United States